Pfizer Declares Q3 2026 Dividend and Secures FDA Approval for IBRANCE Regimen
PFE•Pfizer declared its third-quarter 2026 dividend, payable in September, continuing its quarterly shareholder payouts. The FDA approved its IBRANCE regimen with palbociclib plus trastuzumab and pertuzumab for frontline maintenance in HR-positive, HER2-positive metastatic breast cancer.
1. Third-Quarter 2026 Dividend
On June 24, 2026, Pfizer’s board approved a third-quarter dividend, payable in September. The declaration maintains the company’s uninterrupted streak of quarterly payouts, reinforcing its commitment to returning cash to shareholders.
2. FDA Approval for IBRANCE Regimen
The FDA greenlit Pfizer’s IBRANCE regimen combining palbociclib with trastuzumab and pertuzumab as frontline maintenance for hormone receptor-positive, HER2-positive metastatic breast cancer. This approval expands Pfizer’s oncology portfolio and could drive incremental sales growth in a high-value segment.
